gynecomastia/gin diare

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 28 rezilta yo

Index of suspicion. Case 1: abdominal pain, distension, hard stool, and diarrhea in an 11-year-old boy. Case 2: recurrent otitis media in a 4-year-old boy. Case 3: gynecomastia and galactorrhea in a 15-year-old boy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[Influence of size and duration of gynecomastia on its response to treatment with tamoxifen].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Gynecomastia is treated when it is painful, there are psychosocial repercussions or it does not revert in less than two years. It is treated with the antiestrogenic drug tamoxifen, but there are doubts about its effectiveness in high volume gynecomastias or in those lasting more than two

A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The objective of this study was to evaluate efficacy, safety, and dose-response profiles of four dosing schemes of flutamide over 24 weeks. METHODS Patients were randomized to receive one of the following five treatment regimens for a period of 24 weeks: placebo capsule, flutamide capsules

Clinical response to busramustine (KM-2210) in chronic lymphocytic leukemia: a pilot evaluation of estrogen receptor in relation to its therapeutic effect.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Busramustine (KM-2210), the benzoate of a 17 beta-estradiol-chlorambucil conjugate, was administered to 11 patients with chronic lymphocytic leukemia (CLL) which included eight cases of B-cell CLL and three cases of T-cell CLL. Four patients had received prior chemotherapy. Busramustine was given

Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Goserelin acetate implant is a newly approved depot formulation of a luteinizing hormone-releasing hormone (LHRH) agonist indicated for palliation of advanced prostate cancer. LHRH superagonists suppress gonadotropin release from the pituitary gland by causing down-regulation of receptors. The

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Androgen ablation with luteinizing hormone-releasing hormone (LHRH) agonists, orchiectomy, or oral estrogens has significant untoward sexual side effects. We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma

Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma. In this study, 40 patients with advanced disease were treated with 250 mg flutamide, three times daily. The mean follow-up was 7 months. After 3 months, 35 patients were evaluable

Problems associated with medical treatment of peptic ulcer disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In the United States, the drugs most commonly used to treat peptic ulcer disease are antacids and the H2-receptor antagonists cimetidine and ranitidine. Other available agents include anticholinergics and the coating agent sucralfate. Investigational drugs such as colloidal bismuth, carbenoxolone,

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The treatment for prostate cancer patients with biochemical failure after local therapy remains controversial. Peripheral androgen blockade using a combination of a 5-alpha reductase inhibitor and an antiandrogen may allow control of the prostate-specific antigen (PSA). Because

Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To compare in a randomized clinical trial the therapeutic efficacy of the nonsteroidal antiandrogen flutamide 250 mg tid to testicular androgen suppression by orchidectomy in patients with metastatic prostate cancer. METHODS Between 1989 and 1991, 104 patients aged 74 +/- 8 years with

[The role of bicalutamide in the treatment of prostate cancer].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Bicalutamide is an effective, non-steroidal antiandrogen, suitable for oral, once daily administration. Bicalutamide 50 mg plus LHRHa is at least as effective as flutamide plus LHRHa in terms of survival and time to progression. Monotherapy with bicalutamide 150 mg once daily has similar survival

Hormonal treatment for prostate cancer in Italy. Preliminary data from a survey of the QUABIOS Group.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE An observational study was planned by the QUABIOS group, to survey the hormonal modalities administered to prostate cancer patients in Italy within a time window of 12 months. We report here a summary of treatment schedules and related adverse effects, as recorded at the first

Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The efficacy and tolerability of Casodex, a new non-steroidal antiandrogen, were studied in 267 patients with advanced prostate cancer. All patients received Casodex, 50 mg daily, as monotherapy. The objective response rate was 55.5% and the subjective response rate was 56.1%. The most common

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The safety, efficacy, and pharmacokinetics of the nonsteroidal antiandrogen bicalutamide were investigated in a Phase II trial in 150 patients with metastatic prostate cancer. METHODS Patients took bicalutamide, 50 mg daily, in an open-label multicenter North American trial. RESULTS The

Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE PC-SPES is an herbal supplement for which there are anecdotal reports of anti-prostate cancer activity. This phase II study was undertaken to assess the efficacy and toxicity of PC-SPES in prostate cancer patients. METHODS Thirty-three patients with androgen-dependent prostate cancer

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye